Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics

Age and Ageing

Volumn 39, Issue 4, 2010, Pages 451-458

  Boxer, R S ^b   Kleppinger, A ^a   Brindisi, J ^a   Feinn, R ^a   Burleson, J A ^a   Kenny, A M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cardiovascular risk factors; Dehydroepiandrosterone; Elderly; Lipids

Indexed keywords

CALCIUM; CHOLESTEROL; COLECALCIFEROL; ESTRADIOL; ESTRONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ABDOMINAL FAT; AEROBIC EXERCISE; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; BODY FAT; BREAST DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; FRAIL ELDERLY; GLUCOSE BLOOD LEVEL; GOUT; HAIR GROWTH; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; OVARY DISEASE; PANIC; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; SHORT COURSE THERAPY; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO; WEAKNESS; YOGA; ANALYSIS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; EXERCISE; METABOLISM; RISK FACTOR; VERY ELDERLY;

ABDOMINAL FAT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; CALCIUM; CARDIOVASCULAR DISEASES; CHOLECALCIFEROL; CHOLESTEROL, LDL; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; EXERCISE; FEMALE; FRAIL ELDERLY; HUMANS; LIPIDS; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 77954259803     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afq043     Document Type: Article

References (33)

1. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
2. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ 1993; 307: 349-53.
3. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
4. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
5. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
6. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290: 1042-8.
7. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-56.
8. Orme JG, Reis J, Herz EJ. Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) scale. J Clin Psychol 1986; 42: 28-33.
9. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol 1999; 52: 643-51.
10. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 2004; 151: 1-14.
11. Tummala S, Svec F. Correlation between the administered dose of DHEA and serum levels of DHEA and DHEA-S in human volunteers: analysis of published data. Clin Biochem 1999; 32: 355-61.
12. Igwebuike A, Irving BA, Bigelow ML, Short KR, McConnell JP, Nair KS. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 534-8.
13. Nair KS, Rizza RA, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355: 1647-59.
14. Percheron G, Hogrel JY, Denot-Ledunois S et al. Effect of 1year oral administration of dehydroepiandrosterone to 60to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 2003; 163: 720-7.
15. Villareal DT. Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol 2002; 1: 349-57.
16. Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. Am J Physiol Endocrinol Metab 2006; 291: E1003-8.
17. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004; 292: 2243-8.
18. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) 2000; 53: 561-8.
19. Lipsett M. Steroid hormones. Reproductive Endocrinology. SSCJ Yen, ed. Philadelphia: Saunders, 1978.
20. Noyan V, Yucel A, Sagsoz N. The association of androgenic sex steroids with serum lipid levels in postmenopausal women. Acta Obstet Gynecol Scand 2004; 83: 487-90.
21. Abbasi A, Duthie EH Jr, Sheldahl L et al. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. J Am Geriatr Soc 1998; 46: 263-73.
22. Lasco A, Frisina N, Morabito N et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001; 145: 457-61.
23. Barnhart KT, Freeman E, Grisso JA et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal womenonserumendocrineprofiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896-902.
24. Basu R, Dalla Man C, Campioni M et al. Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes 2007; 56: 753-66.
25. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49: 421-32.
26. Somboonporn W. Testosterone therapy for postmenopausal women: efficacy and safety. Semin Reprod Med 2006; 24: 115-24.
27. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 1509-16.
28. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 2000; 7: 395-401.
29. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
30. Espeland MA, Hogan PE, Fineberg SE et al. Effectofpostmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998; 21: 1589-95.
31. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with crosssex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-42.
32. Christiansen JJ, Andersen NH, Sorensen KE et al. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol (Oxf) 2007; 66: 426-33.
33. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.